IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
Completed · Phase 1
Conditions studied: Metastatic Melanoma
In brief
This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.
Key facts
- Study ID
- NCT04109456
- Run by
- InxMed (Shanghai) Co., Ltd.
- People needed
- 51
- Starts
- 2020-03-16
- Expected to finish
- 2024-12-20
- Last updated by the study team
- 2026-01-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sylvester Comprehensive Cancer Center. — Miami, Florida, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Columbia University Medical Center — New York, New York, United States
- MD Anderson — Houston, Texas, United States
- St Vincent Hospital Sydney — Sydney, New South Wales, Australia
- The Alfred Hospital — Melbourne, Victoria, Australia
- Linear Clinical Research — Nedlands, Western Australia, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.